{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:34Z","timestamp":1793212114024,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fatigue is a debilitating multifactorial symptom experienced by patients with Crohn\u2019s disease (CD). Mirikizumab, an anti-interleukin-23p19 antibody, demonstrated significant efficacy and safety in the patients with moderately to severely active CD. This analysis investigated the impact of mirikizumab on fatigue and the association between changes in clinical, endoscopic, and patient-reported outcomes with improvement in fatigue from baseline in the Phase 3 VIVID-1 study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult patients with moderately to severely active CD that failed at least 1 biologic agent or conventional therapy were randomized to receive mirikizumab or placebo. Fatigue was assessed via the validated Functional Assessment of Chronic Illness Therapy-Fatigue questionnaire. Fatigue associations with patient-reported outcomes, endoscopic, and clinical measures were assessed via Pearson correlation analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At Week 12, 43% and 33%, and at Week 52, 46% and 36% of mirikizumab-treated patients achieved\u2005\u2265\u20056 and\u2005\u2265\u20059 fatigue score improvements vs placebo (Week 12, 31%, 22%; Week 52, 20%, 16%), respectively. Baseline fatigue scores were strongly associated with depressive symptoms and moderately associated with quality of life (QoL) at baseline. Improvements in fatigue at Weeks 12 and 52 were strongly associated with QoL and patient-reported outcomes and weakly with objective markers of inflammation and disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Mirikizumab-treated patients with CD achieved higher rates of clinically meaningful improvement in fatigue vs placebo at Weeks 12 and 52, which correlated with improvement in clinical and patient-reported outcomes. Baseline fatigue severity was strongly associated with depressive symptoms in VIVID-1 (NCT03926130).<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf100","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T06:55:55Z","timestamp":1749538555000},"source":"Crossref","is-referenced-by-count":4,"title":["Impact of mirikizumab treatment on fatigue in patients with moderately to severely active Crohn\u2019s disease: results from the phase 3 VIVID-1 study"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7681-8111","authenticated-orcid":false,"given":"Miguel","family":"Regueiro","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic Foundation , Cleveland, OH ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fischer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Indiana University School of Medicine , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-7365","authenticated-orcid":false,"given":"Peter","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Imelda General Hospital , Bonheiden ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Protic","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Traxler","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanglei","family":"Yu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyu","family":"Zang","sequence":"additional","affiliation":[{"name":"Tigermed-BDM Inc. , Somerset, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Vadhariya","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company , Indianapolis, IN ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-3536","authenticated-orcid":false,"given":"Tadakazu","family":"Hisamatsu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Kyorin University School of Medicine , Mitaka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-5235","authenticated-orcid":false,"given":"Pascal","family":"Juillerat","sequence":"additional","affiliation":[{"name":"Intesto Crohn and Colitis Center , Bern ,","place":["Switzerland"]},{"name":"Department of Visceral Surgery and Medicine, Inselspital Bern University Hospital, University of Bern , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center IRCCS Humanitas Research Hospital , Rozzano, Milan ,","place":["Italy"]},{"name":"Department of Biomedical Sciences, Humanitas University , Pieve Emanuele, Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2090-3445","authenticated-orcid":false,"given":"Javier P","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigaci\u00f3n Sanitaria Princesa (IIS-Princesa), Universidad Aut\u00f3noma de Madrid (UAM), and Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBEREHD) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Walsh","sequence":"additional","affiliation":[{"name":"Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust and NIHR Biomedical Research Centre , Oxford ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025070402470348400_CIT0001","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn\u2019s disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet."},{"key":"2025070402470348400_CIT0002","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/ibd.21285","article-title":"Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort","volume":"16","author":"Romberg-Camps","year":"2010","journal-title":"Inflamm Bowel Dis."},{"key":"2025070402470348400_CIT0003","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2036.2010.04347.x","article-title":"Systematic review: fatigue in inflammatory bowel disease","volume":"32","author":"van Langenberg","year":"2010","journal-title":"Aliment Pharmacol Ther."},{"key":"2025070402470348400_CIT0004","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12325-022-02364-2","article-title":"Burden of fatigue among patients with ulcerative Colitis and Crohn\u2019s Disease: results from a global survey of patients and gastroenterologists","volume":"40","author":"Regueiro","year":"2023","journal-title":"Adv Ther."},{"key":"2025070402470348400_CIT0005","doi-asserted-by":"crossref","first-page":"1424926","DOI":"10.3389\/fmed.2024.1424926","article-title":"Unraveling the fatigue puzzle: insights into the pathogenesis and management of IBD-related fatigue including the role of the gut-brain axis","volume":"11","author":"Truyens","year":"2024","journal-title":"Front Med (Lausanne)."},{"key":"2025070402470348400_CIT0006","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1093\/ibd\/izab006","article-title":"International perspectives on management of inflammatory bowel disease: opinion differences and similarities between patients and physicians from the IBD GAPPS survey","volume":"27","author":"Rubin","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025070402470348400_CIT0007","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"The Lancet"},{"key":"2025070402470348400_CIT0008","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes."},{"key":"2025070402470348400_CIT0009","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1365-2036.2011.04871.x","article-title":"Validation of the functional assessment of chronic illness therapy-fatigue (FACIT-F) in patients with inflammatory bowel disease","volume":"34","author":"Tinsley","year":"2011","journal-title":"Aliment Pharmacol Ther."},{"key":"2025070402470348400_CIT0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s11136-024-03829-3","article-title":"Psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in adults with moderately to severely active Crohn\u2019s disease","volume":"34","author":"Regueiro","year":"2024","journal-title":"Qual Life Res."},{"key":"2025070402470348400_CIT0011","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/ecco-jcc\/jjae083","article-title":"Impact of upadacitinib induction and maintenance therapy on health-related quality of life, fatigue, and work productivity in patients with moderately-to-severely active Crohn\u2019s disease","volume":"18","author":"Ghosh","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025070402470348400_CIT0012","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s41669-023-00419-w","article-title":"Content validity and psychometric evaluation of the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) in patients with Crohn\u2019s Disease and Ulcerative Colitis","volume":"7","author":"Loftus","year":"2023","journal-title":"PharmacoEcon Open."},{"key":"2025070402470348400_CIT0013","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/ibd\/izae166","article-title":"Mirikizumab sustained impact on fatigue in patients with moderately to severely active Crohn\u2019s disease in the phase 2 AMAG study","volume":"31","author":"Regueiro","year":"2024","journal-title":"Inflamm Bowel Dis."},{"key":"2025070402470348400_CIT0014","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/ueg2.12384","article-title":"Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn\u2019s disease: results up to Week 104 of the STARDUST trial","volume":"11","author":"Panes","year":"2023","journal-title":"United European Gastroenterol J."},{"key":"2025070402470348400_CIT0015","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/apt.17242","article-title":"Effect of risankizumab on health-related quality of life in patients with Crohn\u2019s disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials","volume":"57","author":"Peyrin-Biroulet","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"2025070402470348400_CIT0016","volume-title":"Statistical Power Analysis for the Behavioral Sciences. Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"},{"key":"2025070402470348400_CIT0017","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)."},{"key":"2025070402470348400_CIT0018","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cgh.2021.06.034","article-title":"Prevalence and risk factors for fatigue in adults with inflammatory bowel disease: a systematic review with meta-analysis","volume":"20","author":"D\u2019Silva","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025070402470348400_CIT0019","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1749-6632.2001.tb05824.x","article-title":"Cytokines and chronic fatigue syndrome","volume":"933","author":"Patarca","year":"2001","journal-title":"Ann N Y Acad Sci."},{"key":"2025070402470348400_CIT0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s12325-019-01151-w","article-title":"Fatigue in inflammatory bowel diseases: etiologies and management","volume":"37","author":"Nocerino","year":"2020","journal-title":"Adv Ther."},{"key":"2025070402470348400_CIT0021","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1126\/science.abi6087","article-title":"Signaling inflammation across the gut-brain axis","volume":"374","author":"Agirman","year":"2021","journal-title":"Science."},{"key":"2025070402470348400_CIT0022","first-page":"137","article-title":"Elevated IL-17 and TGF-beta serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder","volume":"7","author":"Davami","year":"2016","journal-title":"Basic Clin Neurosci."},{"key":"2025070402470348400_CIT0023","doi-asserted-by":"crossref","first-page":"649144","DOI":"10.3389\/fphar.2021.649144","article-title":"Th17 cells in depression: are they crucial for the antidepressant effect of Ketamine","volume":"12","author":"Cui","year":"2021","journal-title":"Front Pharmacol."},{"key":"2025070402470348400_CIT0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry."},{"key":"2025070402470348400_CIT0025","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/apt.12659","article-title":"Fatigue is highly associated with poor health-related quality of life, disability and depression in newly-diagnosed patients with inflammatory bowel disease, independent of disease activity","volume":"39","author":"Cohen","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2025070402470348400_CIT0026","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.3390\/jcm10184107","article-title":"Prevalence of Fatigue and unrecognized depression in patients with inflammatory bowel disease in remission under immunosuppressants and biologicals","volume":"10","author":"Truyens","year":"2021","journal-title":"J Clin Med."},{"key":"2025070402470348400_CIT0027","doi-asserted-by":"crossref","first-page":"e0181435","DOI":"10.1371\/journal.pone.0181435","article-title":"Fatigue in out-patients with inflammatory bowel disease: prevalence and predictive factors","volume":"12","author":"Villoria","year":"2017","journal-title":"PLoS One."},{"key":"2025070402470348400_CIT0028","doi-asserted-by":"crossref","first-page":"17562848241271987","DOI":"10.1177\/17562848241271987","article-title":"Depression influences fatigue in inflammatory bowel disease amongst other factors: a structural modelling approach","volume":"17","author":"Barnes","year":"2024","journal-title":"Therap Adv Gastroenterol."},{"key":"2025070402470348400_CIT0029","doi-asserted-by":"crossref","first-page":"922","DOI":"10.14309\/ajg.0000000000002630","article-title":"Understanding predictors of fatigue over time in persons with inflammatory bowel disease: the importance of depressive and anxiety symptoms","volume":"119","author":"Bernstein","year":"2024","journal-title":"Am J Gastroenterol."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf100\/63459461\/jjaf100.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjaf100\/63459461\/jjaf100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/7\/jjaf100\/63459461\/jjaf100.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T06:47:14Z","timestamp":1751611634000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf100\/8159223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf100","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,6,10]]},"article-number":"jjaf100"}}